Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Phase 2 Study of CEP-18770 in Relapsed, Refractory Multiple Myeloma
2009-013778-41Phase 2Completed
- Sponsor
- Cephalon, Inc.
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of delanzomib in multiple myeloma (MM), sponsored by Cephalon, Inc. Primary endpoint: Best response to CEP-18770 treatment. Started Apr 2010; status: completed.
02
Drugs
delanzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2009-013778-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013778-41.